JP2003518946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003518946A5 JP2003518946A5 JP2001550313A JP2001550313A JP2003518946A5 JP 2003518946 A5 JP2003518946 A5 JP 2003518946A5 JP 2001550313 A JP2001550313 A JP 2001550313A JP 2001550313 A JP2001550313 A JP 2001550313A JP 2003518946 A5 JP2003518946 A5 JP 2003518946A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- composition
- sequence
- oligomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000008685 targeting Effects 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 15
- 241000194032 Enterococcus faecalis Species 0.000 description 14
- 101150002100 ftsK gene Proteins 0.000 description 14
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 13
- 101150108659 secA gene Proteins 0.000 description 13
- 230000014621 translational initiation Effects 0.000 description 12
- 101100521984 Dictyostelium discoideum psiF gene Proteins 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 11
- 101100331542 Escherichia coli (strain K12) dicC gene Proteins 0.000 description 11
- 101100095302 Streptococcus gordonii secA1 gene Proteins 0.000 description 11
- -1 alkyl hydride Peroxide Chemical class 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 101150064487 dicA gene Proteins 0.000 description 11
- 150000007523 nucleic acids Chemical group 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 10
- 101150000034 dicB gene Proteins 0.000 description 10
- 101150101609 ftsA gene Proteins 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 8
- 101100366267 Bacillus subtilis (strain 168) spoIIIE gene Proteins 0.000 description 7
- 101100327514 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) cfbE gene Proteins 0.000 description 7
- 101100355952 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) rcp gene Proteins 0.000 description 7
- 101150069320 ddl gene Proteins 0.000 description 7
- 101150109034 ddlA gene Proteins 0.000 description 7
- 101150046743 ddlB gene Proteins 0.000 description 7
- 101150027005 divIB gene Proteins 0.000 description 7
- 101150005487 ftsI gene Proteins 0.000 description 7
- 101150071760 ftsL gene Proteins 0.000 description 7
- 101150069904 ftsN gene Proteins 0.000 description 7
- 101150026421 ftsQ gene Proteins 0.000 description 7
- 101150043569 ftsW gene Proteins 0.000 description 7
- 101150010079 mraZ gene Proteins 0.000 description 7
- 101150034514 murC gene Proteins 0.000 description 7
- 101150093075 murD gene Proteins 0.000 description 7
- 101150043597 murE gene Proteins 0.000 description 7
- 101150060462 pbpB gene Proteins 0.000 description 7
- 101150014273 rsmH gene Proteins 0.000 description 7
- 101150093914 seqA gene Proteins 0.000 description 7
- 101150073502 sulA gene Proteins 0.000 description 7
- 101150096853 zipA gene Proteins 0.000 description 7
- 101150111615 ftsZ gene Proteins 0.000 description 6
- 101150067055 minC gene Proteins 0.000 description 6
- 101150102210 murF gene Proteins 0.000 description 6
- 101150037968 murG gene Proteins 0.000 description 6
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 6
- 108020004827 Carbamate kinase Proteins 0.000 description 5
- 108020003338 D-alanine-D-alanine ligase Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 5
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 5
- 101710183280 Topoisomerase Proteins 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 101150110189 minE gene Proteins 0.000 description 5
- 101150074096 mraY gene Proteins 0.000 description 5
- 241000194031 Enterococcus faecium Species 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 241001455617 Sula Species 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 3
- STPYXSIUEAXIFH-UHFFFAOYSA-N oxathiasilirane 2,2-dioxide Chemical compound O=S1(=O)O[SiH2]1 STPYXSIUEAXIFH-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 101100301559 Bacillus anthracis repS gene Proteins 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 101100247969 Clostridium saccharobutylicum regA gene Proteins 0.000 description 2
- 101100412434 Escherichia coli (strain K12) repB gene Proteins 0.000 description 2
- 101000581498 Methylosinus trichosporium Methanobactin mb-OB3b Proteins 0.000 description 2
- 101100114425 Streptococcus agalactiae copG gene Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 241000589884 Treponema pallidum Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 101150044854 repA gene Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 108091003202 SecA Proteins Proteins 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17448400P | 2000-01-04 | 2000-01-04 | |
| US60/174,484 | 2000-01-04 | ||
| PCT/US2001/000222 WO2001049775A2 (en) | 2000-01-04 | 2001-01-04 | Antisense antibacterial cell division composition and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003518946A JP2003518946A (ja) | 2003-06-17 |
| JP2003518946A5 true JP2003518946A5 (https=) | 2008-02-14 |
Family
ID=22636319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001550313A Pending JP2003518946A (ja) | 2000-01-04 | 2001-01-04 | アンチセンス抗細菌性細胞分裂組成物、およびその方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7049431B2 (https=) |
| EP (1) | EP1248813A2 (https=) |
| JP (1) | JP2003518946A (https=) |
| KR (1) | KR20020079768A (https=) |
| AU (1) | AU781676B2 (https=) |
| CA (1) | CA2396068A1 (https=) |
| WO (1) | WO2001049775A2 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6720139B1 (en) | 1999-01-27 | 2004-04-13 | Elitra Pharmaceuticals, Inc. | Genes identified as required for proliferation in Escherichia coli |
| KR20020064915A (ko) * | 1999-11-29 | 2002-08-10 | 에이브이아이 바이오파마 인코포레이티드 | 안티센스 항박테리아 방법 및 조성물 |
| US6764823B2 (en) | 2000-04-06 | 2004-07-20 | Pharmacia & Upjohn Company | Antimicrobial methods and materials |
| US6784291B2 (en) * | 2000-05-04 | 2004-08-31 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
| JP2005503831A (ja) * | 2001-09-28 | 2005-02-10 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | 抗微生物方法および材料 |
| CA2523672C (en) | 2003-04-29 | 2012-07-17 | Avi Biopharma, Inc. | Compositions for enhancing transport of molecules into cells |
| AU2004263124B2 (en) * | 2003-08-07 | 2009-01-15 | Avi Biopharma, Inc. | Sense antiviral compound and method for treating ssRNA viral infection |
| US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
| US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| EP1713332A4 (en) | 2004-01-23 | 2010-08-18 | Avi Biopharma Inc | ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION |
| US7402574B2 (en) * | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
| USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| ATE498685T1 (de) | 2004-06-28 | 2011-03-15 | Univ Western Australia | Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon |
| ATE510914T1 (de) * | 2004-07-02 | 2011-06-15 | Avi Biopharma Inc | Antisinn antibakterielle verfahren und verbindungen |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
| US20060293268A1 (en) * | 2005-05-05 | 2006-12-28 | Rieder Aida E | Antisense antiviral compounds and methods for treating foot and mouth disease |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| US8329668B2 (en) * | 2005-09-08 | 2012-12-11 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
| WO2007117371A2 (en) * | 2006-03-01 | 2007-10-18 | Anza Therapeutics, Inc. | Engineered listeria and methods of use thereof |
| CA2644262C (en) * | 2006-03-07 | 2016-01-05 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
| DK2735568T3 (da) * | 2006-05-10 | 2017-11-13 | Sarepta Therapeutics Inc | Oligonukleotidanaloger med kationiske bindinger mellem underenheder |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| EP2235034B1 (en) | 2007-12-28 | 2016-11-23 | Sarepta Therapeutics, Inc. | Immunomodulatory agents and methods of use |
| CN112574988A (zh) | 2008-10-24 | 2021-03-30 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| AU2009335740B2 (en) * | 2008-12-17 | 2016-04-21 | Sarepta Therapeutics, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| LT2499249T (lt) | 2009-11-12 | 2018-12-27 | The University Of Western Australia | Priešprasmės molekulės ir patologijų gydymo būdai |
| AU2010319314C1 (en) | 2009-11-13 | 2016-09-01 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US9050373B2 (en) | 2010-05-13 | 2015-06-09 | The Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same |
| KR20200133284A (ko) | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| ES2639420T3 (es) | 2010-11-10 | 2017-10-26 | Nigel L. Webb | Nucliones y ribocápsides |
| EP2672977A1 (en) | 2011-02-08 | 2013-12-18 | The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System | Antisense oligonucleotides |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| EA202090338A1 (ru) | 2011-11-18 | 2021-04-30 | Сарепта Терапьютикс, Инк. | Функционально-модифицированные олигонуклеотиды и их субъединицы |
| JP6542662B2 (ja) | 2012-03-20 | 2019-07-10 | サレプタ セラピューティクス， インコーポレイテッド | オリゴヌクレオチドアナログのボロン酸結合体 |
| NZ731587A (en) | 2013-03-14 | 2021-07-30 | Sarepta Therapeutics Inc | Exon skipping compositions for treating muscular dystrophy |
| US9777274B2 (en) | 2013-03-15 | 2017-10-03 | Techulon Inc. | Antisense molecules for treatment of staphylococcus aureus infection |
| CA2906812A1 (en) | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
| EP2790017A1 (en) * | 2013-04-11 | 2014-10-15 | Institut Pasteur | Methods to obtain a novel class of gram negative bacteria antibiotics which target an unknown cell division associated protein LOP1 |
| WO2016123628A1 (en) * | 2015-01-30 | 2016-08-04 | The Regents Of The University Of Colorado, A Body Corporate | Sequence specific and organism specific antimicrobials and related materials and methods |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| EP3302489A4 (en) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES |
| WO2018140613A1 (en) * | 2017-01-25 | 2018-08-02 | The Board Of Trustees Of The University Of Illinois | Conformation switchable antimicrobial peptides and methods of using the same |
| EP4384620A4 (en) * | 2021-08-13 | 2025-09-17 | 1E Therapeutics Ltd | DNAZYMES TARGETING CELL WALL SYNTHESIS ENZYMES AND THEIR USES |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3398378B2 (ja) * | 1989-12-20 | 2003-04-21 | アンチビラルス・インコーポレイテツド | リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー |
| US5852188A (en) * | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
| US5821052A (en) | 1992-04-16 | 1998-10-13 | University Of Medicine And Dentistry Of New Jersey | Control of the synthesis of proteins by anitisense RNA-tRNA complex |
| US6060456A (en) * | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
| GB9505438D0 (en) * | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| WO1998003533A1 (en) | 1996-07-24 | 1998-01-29 | Oligos Etc. And Oligos Therapeutics, Inc. | Antisense oligonucleotides as antibacterial agents |
| DE69829469D1 (de) * | 1997-01-24 | 2005-04-28 | Avi Biopharm Inc | Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen |
| IL132941A0 (en) * | 1997-05-21 | 2001-03-19 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
| US6204019B1 (en) | 1997-06-04 | 2001-03-20 | Smithkline Beecham Corporation | Sec A2 from Streptococcus pneumoniae |
| US6610539B1 (en) * | 1997-07-10 | 2003-08-26 | Genesense Technologies, Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
| EP0894857A3 (en) | 1997-08-01 | 2001-09-26 | Smithkline Beecham Corporation | SecA gene from Streptococcus pneumoniae |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6228579B1 (en) * | 1997-11-14 | 2001-05-08 | San Diego State University Foundation | Method for identifying microbial proliferation genes |
-
2001
- 2001-01-04 WO PCT/US2001/000222 patent/WO2001049775A2/en not_active Ceased
- 2001-01-04 US US09/754,468 patent/US7049431B2/en not_active Expired - Lifetime
- 2001-01-04 CA CA002396068A patent/CA2396068A1/en not_active Abandoned
- 2001-01-04 AU AU26282/01A patent/AU781676B2/en not_active Expired
- 2001-01-04 EP EP01900867A patent/EP1248813A2/en not_active Withdrawn
- 2001-01-04 JP JP2001550313A patent/JP2003518946A/ja active Pending
- 2001-01-04 KR KR1020027008681A patent/KR20020079768A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003518946A5 (https=) | ||
| US7049431B2 (en) | Antisense antibacterial cell division composition and method | |
| US7238675B2 (en) | Antisense antibacterial method and composition | |
| ES2938623T3 (es) | Método para convertir una secuencia del genoma de una bacteria gram-positiva mediante una conversión específica de una base de ácido nucleico de una secuencia de ADN seleccionada como diana y el complejo molecular utilizado en el mismo | |
| AU2005327188C1 (en) | Antisense antibacterial method and compound | |
| AU2025202594A9 (en) | Modified Cpf1 guide RNA | |
| US8536147B2 (en) | Antibacterial antisense oligonucleotide and method | |
| CN105646719A (zh) | 一种高效定点转基因的工具及其应用 | |
| WO2008008113A1 (en) | Improved antibacterial antisense oligonucleotide and method | |
| Widom et al. | Instability of rRNA operons in Bacillus subtilis | |
| Cove | The moss, Physcomitrella patens. | |
| Peralta et al. | Engineering the nifH promoter region and abolishing poly-β-hydroxybutyrate accumulation in Rhizobium etli enhance nitrogen fixation in symbiosis with Phaseolus vulgaris | |
| CA2817090A1 (en) | Antisense antibacterial compounds and methods | |
| US6136602A (en) | Oligonucleotides specific for the marORAB operon | |
| Sandvang et al. | Translocation of integron-associated resistance in a natural system: acquisition of resistance determinants by Inc P and Inc W plasmids from Salmonella enterica Typhimurium DT104 | |
| Kropinski et al. | Nucleotide sequence of the Pseudomonas aeruginosa insertion sequence IS222: another member of the IS3 family | |
| CN106497880A (zh) | 基因修饰的间充质干细胞及其用于生产BsAb抗体的方法 | |
| IE59562B1 (en) | Method for preparing proteins using transformed lactic acid bacteria | |
| MXPA02004782A (es) | Genes del empequenecimiento del sorgo y metodos de uso. | |
| أ. م. د. رعد ناجي حسن | In silico design bacterial expression vectors of therapeutic strategies of lethal-micro-RNA-7 | |
| CN121294484A (zh) | 一种提高脱氮生丝微菌重组效率的方法及应用 | |
| Siddika | Hierarchical Construction of Catalytic RNA Nanostructures through Oligomerization of Designed Unit Structures Derived from Natural Large Ribozymes | |
| Šťastná et al. | Lactobacilli: Unusual Genome Complexity with Huge Adaptability to the Environment | |
| CA2500397A1 (en) | Aav itr-mediated modulation | |
| CN117844852A (zh) | 一种水稻根际环境特异性诱导表达的启动子、载体、转化体及应用 |